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a b s t r a c t 
Detection of endogenous anabolic androgenic steroids (EAAS) misuse is a major challenge in doping con- 
trol analysis. Currently, a number of endogenous steroids, which constitute the steroid profile, are quanti- 
fied using gas chromatography (GC). With this methodology, only the sum of the free and glucuronidated 
steroids is measured together. A dilute-and-shoot LC-MS method, which is compliant with the quality 
requirements for measuring EAAS established by the World Anti-Doping Agency (WADA), was devel- 
oped and validated containing glucuronidated and sulfated steroids in order to gain some extra infor- 
mation and to expand the existing steroid profile. The developed method is, to the best of our knowl- 
edge, the first method to combine both steroid glucuronides and sulfates, which is compliant with the 
quality standards of the technical document on EAAS, established by WADA. The first advantage of this 
new steroid profile is the reduced sample preparation time, as it is a direct injection method of diluted 
urine. A second advantage is the ability of the used gradient to separate 5 α-androstane-3 α,17 β-diol- 
3-glucuronide (5 ααβdiol3G), 5 α-androstane-3 α,17 β-diol-17-glucuronide (5 ααβdiol17G), 5 β-androstane- 
3 α,17 β-diol-3-glucuronide (5 βαβdiol3G) and 5 β-androstane-3 α,17 β-diol-17-glucuronide (5 βαβdiol17G) 
allowing to gain specific information on these isomers, which cannot be accomplished in GC-MS screen- 
ing due to hydrolysis. This steroid profile also contains free testosterone, 5 α-androstane-3,17-dione and 
5 β-androstane-3,17-dione as markers of degradation. In total, 17 compounds and 10 isotopically labelled 
internal standards are included in this method. 
© 2020 Elsevier B.V. All rights reserved. 
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0. Introduction 
Endogenous anabolic androgenic steroids (EAAS) are substances
roduced in the human body and are related to the metabolic
athways of testosterone. In the clinical field, the measurement of
teroids is very important for therapeutic drug monitoring, the di-
gnosis and monitoring of endocrine disorders and cancers (e.g.,
reast, prostate and endometrium). Highly sensitive and specific
ethods are needed for an accurate diagnosis and the measure-
ent of low concentrations of steroids. The most common matri-
es for steroid analysis are serum, plasma, urine and saliva [1–4] . 
As the use of EAAS can enhance sports performances, it is pro-
ibited by the World Anti-doping Agency (WADA) [5] . An abuse
ith this class of doping substances is difficult to track down be-
ause these steroids are also formed endogenously [6–19] . Fur-
hermore, there is a large inter-individual variation in concen-∗ Corresponding author. 
E-mail address: Laurie.DeWilde@UGent.be (L. De Wilde). 
1 Doping Control Laboratory (DoCoLab), Ghent University, Department Diagnostic 
ciences, Technologiepark 30 B, B-9052 Zwijnaarde, Belgium. 
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021-9673/© 2020 Elsevier B.V. All rights reserved. rations of EAAS, which makes population limits insufficient to
onfirm whether an elevated concentration is a result of steroid
buse. To circumvent this problem, the athlete’s steroidal pass-
ort was introduced, as a part of the athlete’s biological pass-
ort (ABP), which contains basal concentrations of EAAS and ra-
ios among them, with the testosterone/epitestosterone ratio (T/E)
s the most important marker [ 8 , 9 , 11 , 16–21 ]. By using the adaptive
odel, individual reference limits can be established which allow
he comparison of a measured value with results from previous
ests [ 8 , 9 , 11 , 16–19 , 21 ]. When suspicious results are found, a con-
rmation by gas chromatography-combustion-isotope ratio mass 
pectrometry (GC-C-IRMS) is performed to confirm the endoge-
ous or exogenous origin of the steroids [ 9 , 11 , 13 , 15–17 , 19 , 20 , 22 ],
lthough eventually the ABP could also by itself be used to prose-
ute a doping infraction. 
The extensive metabolism of EAAS is divided into two phases.
n phase I, oxidations and reductions occur to inactivate the com-
ound and to facilitate its elimination. In phase II, the steroid is
oupled to glucuronic acid or a sulfate group by conjugation re-
ctions, making the steroid more polar, which also facilitates its
rinary excretion [ 7–9 , 14 , 15 , 17 , 22–27 ]. For example, 3 α-hydroxy
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a  steroids are conjugated with glucuronic acid, while 3 β-hydroxy
steroids are conjugated as sulfates [ 7 , 17 , 28 ]. Glucuronidation and
sulfatation at the 17 β-hydroxy group are well known for testos-
terone. The major metabolites of AAS are glucuronidated, however
some EAAS are also excreted as sulfates [ 7 , 14–18 , 22 , 25 ]. 
In the current steroid profile, constituted by concentrations of
EAAS and ratios among them, only glucuronidated steroids are in-
cluded, as T is mainly conjugated by UGT2B17 and mainly excreted
in a glucuronidated form [ 11 , 13 , 16–18 , 20 , 22 , 24 , 29 ]. Hence, conven-
tional sample preparation methods include an enzymatic hydrol-
ysis step to release the aglycones, whereby information on the
free or sulfoconjugated fraction is lost. Subsequently, the samples
are preconcentrated and analysed by GC-MS after derivatisation
[ 8 , 9 , 13 , 15–18 , 20 , 22–25 , 27 ]. These steps can be time-consuming
and a source of variation, technical errors and inaccuracy [ 17 , 21 ]. 
As some people have a decreased glucuronidation of steroids,
and consequently a lower T/E because of a deletion/deletion
(del/del) polymorphism in UGT2B17, it would be interesting to ex-
pand the steroid profile, to gain some information on free steroids
and to include the sulfoconjugated steroids [ 8 , 9 , 11 , 16 , 18 , 19 , 24 , 28 ].
Previously, the group of Dehennin et al. suggested the ratio be-
tween TG and the sum of EG and ES [ 9 , 28 ] and the ratio be-
tween EG and ES [9] to distinguish between a physiologically and
a pharmacologically high T/E, which was contradicted by the work
of Borts et al. [27] . Another advantage of the addition of sulfate
conjugates is the improvement of detection windows [ 11 , 19 , 24 , 30 ].
Previous studies have shown the usefulness of epiandrosterone sul-
fate (EpiAS), which is known to be only excreted as a sulfoconju-
gate [ 19 , 31–33 ]. Androsterone sulfate (AS) and etiocholanolone sul-
fate (EtioS) were also highlighted as promising markers after oral
testosterone undecanoate intake [ 8 , 9 ]. 
Unfortunately, inclusion of the sulfoconjugated steroids into the
existing GC-MS methods is difficult to achieve due to hydrolysis
and extraction problems [ 6 , 22–24 , 27 ]. Additionally, hydrolysis of
the sulfonjugates yields the same aglycones as glucuronides and
information on the phase II metabolites is lost. 
Previously, LC-MS has proven to be the ideal technique to anal-
yse phase II metabolites of EAAS without the need to hydrolyse
[ 6 , 8 , 9 , 11 , 12 , 14 , 15 , 18–20 , 23 , 25 , 27 , 34 ]. Some research groups anal-
ysed intact glucuronides [12] , intact sulfates [ 6 , 11 , 19 ] or a com-
bination of both [ 8 , 9 , 15 , 18 , 25 , 27 ]. Except for the method of Pozo
et al. [12] , these methods apply solid phase extraction (SPE) as
sample preparation. Previous research in our laboratory has shown
that even by using a dilute-and-shoot-LC-MS (DS-LC-MS) approach,
steroid phase II metabolites can be detected [ 12 , 35 ]. 
The aim of the study was to develop and validate a method that
can determine the steroid profile in urine at the same quality stan-
dards as the currently used GC-MS methodology, while providing
additional information on the nature of the steroid conjugates and
allowing for the concurrent detection of free testosterone using LC-
MS/MS. 
2. Materials and methods 
2.1. Chemicals and reagents 
Water and methanol (MeOH) were purchased from J. T. Baker
(Deventer, The Netherlands). Formic acid (HCOOH) was ob-
tained from Fisher Scientific (Geel, Belgium). Ammonium formate
(NH 4 OOCH) was bought from Fisher Scientific (Loughborough,
Leicestershire, UK). 5 α-androstane-3 α,17 β-diol-3-glucuronide
(5 ααβdiol3G), 5 α-androstane-3 α,17 β-diol-17-glucuronide
(5 ααβdiol17G), 5 α-androstane-3 α,17 β-diol-17-glucuronide-d4,
5 β-androstane-3 α,17 β-diol-3-glucuronide (5 βαβdiol3G), 5 β-
androstane-3 α,17 β-diol-17-glucuronide (5 βαβdiol17G), andros-
terone glucuronide (AG), androsterone glucuronide-d4 (AG-d4),ndrosterone sulfate, androsterone sulfate-d4 (AS-d4), epitestos-
erone glucuronide (EG), epitestosterone glucuronide-d3 (EG-d3),
pitestosterone sulfate (ES), epitestosterone sulfate-d3 (ES-d3),
tiocholanolone glucuronide (EtioG), etiocholanolone sulfate,
tiocholanolone sulfate-d5 (EtioS-d5), testosterone-d3 (T-d3),
estosterone glucuronide (TG), testosterone glucuronide-d3 (TG-
3), testosterone sulfate (TS) and testosterone sulfate-d3 (TS-d3)
ere bought from NMI (Pymble, Australia). 5 α-androstane-
,17-dione was purchased from Steraloids (Newport, R. I.), 5 β-
ndrostane-3,17-dione and testosterone from Sigma-Aldrich
Bornem, Belgium). Dehydroepiandrosterone sulfate (DHEAS) and
ehydroepiandrosterone sulfate-d5 (DHEAS-d5) were bought from
erilliant (Round Rock, Texas). Epiandrosterone sulfate (EpiAS) was
urchased from TRC (Toronto, Canada). 
.2. Instruments 
The LC-MS/MS system consists of a Thermo Scientific Ultimate
0 0 0, with a heated column compartment thermostated at 55 °C
nd an XRS open autosampler, connected to a TSQ Vantage (both
rom Thermo Fisher Scientific). The separation of the compounds
as performed on a Zorbax Eclipse Plus (C18 2.1 × 100 mm; 1.8
m, Agilent Technologies). 
.2.1. LC gradient 
The mobile phases consisted of (A) water and (B) methanol
oth containing 0.01 % HCOOH/5 mM NH 4 OOCH. A gradient elu-
ion program started with 0 % B for 0.1 min after which it was
mmediately increased to 35 %. After 1 min of 35 % B, the gradient
as further increased to 45 % B in 5 min, where it was kept for 5
in and was then increased to 50 % in 19 min. For 4.5 min, the
radient increased to 90 % B, after which it increased to 100 % in
.5 min. This condition was kept for 2 min. The gradient decreased
o starting conditions in 0.1 min and was kept for 0.9 min. 
.2.2. MS parameters 
Detection of the steroids was carried out by electrospray ion-
zation (ESI) in the selective reaction mode (SRM) and tuned S-
ens values were used. The capillary temperature was set to 350 °C.
heath gas pressure, aux gas pressure and ion sweep gas pressure
ere set to 45, 30 and 0.5 arbitrary units respectively. The spray
oltage for positive and negative polarity was set to 40 0 0 V and
0 0 0 V, respectively. The collision gas pressure was 1.5 mTorr. 
Two transitions were found for each compound ( Table 1 ). Some
ompounds have the same mass and so the same transitions are
pplied for these compounds. Although it was difficult to separate
HEAS and ES, transitions specific for ES were found and included
s well. 
.3. Sample preparation 
Steroid stripped urine was prepared by pouring urine of a child
n a preconditioned XAD-2 column. Aliquots of 300 μl were pre-
ared. Steroid stripped urine was spiked at six calibration lev-
ls using two different calibration mixes, which were prepared in
ethanol. The concentration of mix 1 was 10 times higher than
he lowest calibrator. The concentration of mix 2 was 5 times
igher than the concentration of the fourth calibrator. 30, 60 and
00 μl of calibration mix 1 were added to calibrators 1,2 and 3
espectively. 60, 120 and 240 μl of calibration mix 2 was added to
alibrator 4,5 and 6 respectively. The calibration mixes did not con-
ain 5 α-androstane-3,17-dione and 5 β-androstane-3,17-dione, be-
ause there was no need for wide calibration ranges for these two
ompounds. Therefore, 6, 15, 22.5, 30, 60 and 120 μl of a 5 α-
ndrostane-3,17-dione solution (1 μg/ml) were added to calibrators
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Table 1 
Transitions and collision energies (CE) for every compound. 
Compound Chemical formula Polarity Parent Product CE (eV) 
5 ααβdiol3G C 25 H 40 O 8 - 467.2 84.9 ∗ 40 
74.9 40 
5 ααβdiol17G C 25 H 40 O 8 - 467.2 84.9 ∗ 40 
74.9 40 
5 ααβdiol17G-d4 C 25 D 4 H 36 O 8 - 471.2 84.9 40 
5 α-androstane-3,17-dione C 19 H 28 O 2 + 289.2 213.2 ∗ 16 
271.2 8 
5 βαβdiol3G C 25 H 40 O 8 - 467.2 84.9 ∗ 40 
74.9 40 
5 βαβdiol17G C 25 H 40 O 8 - 467.2 84.9 ∗ 40 
74.9 40 
5 β-androstane-3,17-dione C 19 H 28 O 2 + 289.2 213.2 ∗ 16 
271.2 8 
AG C 25 H 38 O 8 - 465.2 85.0 
∗ 35 
+ 484.0 141.0 30 
AG-d4 C 25 D 4 H 34 O 8 - 469.2 85.0 30 
AS C 19 H 30 O 5 S - 369.2 96.9 
∗ 35 
80.0 60 
AS-d4 C 19 D 4 H 26 O 5 S - 373.1 97.9 35 
DHEAS C 19 H 28 O 5 S - 367.1 96.9 
∗ 45 
80.1 80 
DHEAS-d5 C 19 D 5 H 23 O 2 - 372.1 97.8 45 
EpiAS C 19 H 30 O 5 S - 369.2 96.9 
∗ 35 
80.0 60 
EG C 25 H 36 O 8 - 463.2 85.0 
∗ 35 
+ 465.3 289.4 19 
EG-d3 C 25 D 3 H 33 O 8 - 466.2 85.0 25 
ES C 19 H 28 O 5 S - 367.1 96.9 
∗ 45 
+ 369.2 271.2 13 
ES-d3 C 19 D 3 H 25 O 5 S - 370.1 97.9 40 
EtioG C 25 H 38 O 8 - 465.2 85.0 
∗ 35 
+ 484.0 141.0 30 
EtioS C 19 H 30 O 5 S - 369.2 96.9 
∗ 35 
80.0 60 
EtioS-d5 C 19 D 5 H 25 O 5 S - 374.1 80.0 35 
T C 19 H 28 O 2 + 289.2 97.0 ∗ 25 
109.0 27 
T-d3 C 19 D 3 H 25 O 2 + 292.2 97.0 21 
TG C 25 H 36 O 8 + 465.3 289.4 ∗ 19 
108.9 39 
TG-d3 C 25 D 3 H 33 O 8 + 468.0 97.0 30 
TS C 19 H 28 O 5 S - 367.1 96.9 
∗ 45 
+ 369.2 97.0 30 
TS-d3 C 19 D 3 H 25 O 5 S - 370.1 98.0 50 
∗ Ion transitions used for quantification. 
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v   to 6 respectively and 6, 12, 30, 60, 120 and 240 μl of a 5 β-
ndrostane-3,17-dione solution (500 ng/ml) was added to calibra-
ors 1 to 6 respectively. Table 2 presents the concentrations of the
teroid conjugates in every calibration sample. 
50 μl internal standard methanolic solution(5 ααβdiol17G-d4,
G-d4, AS-d4, DHEAS-d5, EG-d3, ES-d3, EtioS-d5, T-d3, TG-d3; 1
g/ml) was added to an aliquot of 300 μl urine. The sample was
hen centrifuged (5 min, 50 0 0 x g) and the supernatant was trans-
erred to a vial. 80 μl of sample was injected into the system. 
.4. Validation 
The steroids analysed with this method are endogenously pro-
uced and naturally found in urine samples. Therefore steroid
tripped urine was chosen as a surrogate matrix to validate the
uantitative aspects of the method; i.e., preparation of the cali-
ration curve, internal bias, repeatability and intermediate preci-
ion. Selectivity, matrix effect, external bias and compliance with
ADA’s stringent demands for quantitation were tested with real
rine samples. .4.1. Linearity 
Three replicates of the calibration curve were prepared by
piking steroid stripped urine at 6 concentration levels (cf. 2.3)
n compound-specific ranges ( Table 3 ) and evaluated using a
eighted regression model (1/X). Linearity was evaluated at three
evels, namely R ², bias per level and the goodness-of-fit factor (g-
actor, g) calculated by the formula: g = 
√ ∑ 
( % bias ) 2 
n −1 , with n being
he number of calibrators. The maximum value for the goodness-
f-fit factor depended on the concentration of the calibrators. If the
oncentration of more than half of the calibrators was below 100
g/ml, the maximum g-factor value was 20. If the concentration of
ore than half of the calibrators was above 100 ng/ml, the allowed
-factor value was 10. 
.4.2. Bias and precision 
Bias and precision were evaluated at the highest, the lowest
nd the fourth calibrator. To evaluate repeatability, the ratio of
he standard deviation and the nominal concentration was cal-
ulated. Intermediate precision was assessed by two analysts on
hree separate days. External bias could only be evaluated for
he glucuronidated steroids as there were no external reference
alues for the sulfated steroids available. 25 external quality as-
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Table 2 
Concentrations of the steroid conjugates in every calibration sample. 
Compound C1 C2 C3 C4 C5 C6 
5 ααβdiol3G 5 10 50 200 400 800 ng/ml 
5 ααβdiol17G 5 10 50 200 400 800 ng/ml 
5 α-androstane-3,17-dione 20 50 75 100 200 400 ng/ml 
5 βαβdiol3G 5 10 50 200 400 800 ng/ml 
5 βαβdiol17G 5 10 50 200 400 800 ng/ml 
5 β-androstane-3,17-dione 10 20 50 100 200 400 ng/ml 
AG 200 400 2000 3000 6000 12000 ng/ml 
AS 50 100 500 750 1500 3000 ng/ml 
DHEAS 20 40 200 2000 4000 8000 ng/ml 
EpiAS 15 30 150 250 500 1000 ng/ml 
EG 2 4 20 50 100 200 ng/ml 
ES 2 4 20 30 60 120 ng/ml 
EtioG 200 400 2000 3000 6000 12000 ng/ml 
EtioS 20 40 200 250 500 1000 ng/ml 
T 0.1 0.2 1 2.5 5 10 ng/ml 
TG 1 2 10 50 100 200 ng/ml 
TS 1 2 10 12.5 25 50 ng/ml 
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Csessment scheme (EQAS) samples, organised by WADA and anal-
ysed by all WADA–accredited doping control laboratories, were
analysed and z-scores were calculated using the following for-
mula: z = measured v alue − assigned v alue 
t arget v alue f or st and ard d e v iation . In this equation, the tar-
get value for standard deviation depends on the compound. The
allowed standard deviation is 25 % for the diols, 20 % for A,
Etio, T and E and 15 % for the T/E ratio as defined by the In-
ternational Standard for Laboratories by WADA [36] . To be able
to compare the EQAS results with the results of the devel-
oped method, the concentrations of the glucuronides were ex-
pressed as concentrations of the free steroids whereby the con-
centrations of 5 αdiol and 5 βdiol were the sums of their respec-
tive glucuronide isomers (5 αdiol = 5 ααβdiol3G + 5 ααβdiol17G;
5 βdiol = 5 βαβdiol3G + 5 βαβdiol17G). 
2.4.3. Matrix effect 
As the AAS in this method are naturally present in urine, de-
termination of the matrix effect was difficult. To circumvent this
problem, a previously used approach was applied [12] . Ten urines
(specific gravity between 1.004 and 1.035; pH between 5.1 and 7.2)
and a water sample were spiked with the internal standards. The
average area of the internal standards in the urine samples was
compared to the area in the water sample and the matrix effect
was calculated with the formula: matrix effect (%) = ((urine/water
area ratio) x 100) – 100 [37] . 
2.4.4. Carry-over 
Carry-over was assessed by analysing a blank matrix sample af-
ter an injection of the highest calibrator. 
2.4.5. Quality control samples 
With each batch of samples, 2 quality control (QC) sampleswere
analysed. These QCs existed of steroid stripped urine spiked at 2
different levels ( Table 3 ). The low QC (5LOQ) was spiked with 150
μl of the first calibration mix, 18 μl of 5 α-androstane-3,17-dione
(1 μg/ml) and 21 μl of 5 β-androstane-3,17-dione (500 ng/ml). The
high QC was spiked with 90 μl of the second calibration mix, 45 μl
of 5 α-androstane-3,17-dione (1 μg/ml) and 90 μl of 5 β-androstane-
3,17-dione (500 ng/ml). 
2.4.6. Measurement uncertainty 
Measurement uncertainty was determined with the use of in-
termediate precision, QC and EQAS results, using the following for-
mula: u c (y ) = 
√ 
S 2 w + u ( B ext ) 2 . In this equation, u c (y) represents
the standard combined uncertainty associated with an individualesult; S w is the intermediate precision calculated by the following
ormula: S w = 
√ 
Bias % 2 + RSD % 2 and B ext is the external bias deter-
ined by the average bias in EQAS samples, which was calculated
ith the measured concentrations of the conjugates expressed as
oncentrations of the free steroids. This was only calculated for
he parameters of the current steroid profile and at three differ-
nt levels, namely LOQ, QC1 and QC2. Measurement uncertainty,
escribed in WADA’s technical document on EAAS [38] and deci-
ion limits [39] , cannot exceed 30 % at the respective LOQ, 20 %
or A and Etio or 25 % for the diols at 5 times the LOQ and 20 %
or T and E when the concentration is greater than 5 ng/ml. 
.5. Comparison with routine GC method 
70 routine samples, previously analysed with the GC routine
ethod [40] , were analysed with the developed LC method. Re-
ults were compared using Bland-Altman plots, which express the
bsolute difference between a sample measured on GC and on LC
lotted against the mean of the two measurements, and linear re-
ression plots. 
.6. Excretion study 
One capsule of testosterone undecanoate (TU) (Testocaps, 40
g) was administered orally to 6 healthy, male volunteers (age:
3-26 years, weight: 64-94 kg). Blank urine samples were collected
or one week before administration in the morning, at noon and in
he evening. A blank sample was delivered just before administra-
ion as well. Post-administration samples were collected at 2 h, 4
, 6 h, 8 h, 10 h, 12 h, 24 h, 30 h, and 36 h. From then on sam-
les were collected in the morning, at noon and in the evening. All
amples were stored frozen (-20 °C) until analysis. This study was
pproved by the ethics committee of the Ghent University Hospital
B67020064707). Each volunteer gave his written informed consent
rior to the study. 
Results were compared between the developed method and the
outine GC method [40] by expressing the results of the LC method
s concentrations of the free steroids. The concentrations of 5 αdiol
nd 5 βdiol were the sums of their respective glucuronide iso-
ers. To compare urine samples longitudinally, concentrations of
he studied steroids were corrected for dilution using the equation
 1 . 020 = 1 . 020 − 1 Speci f ic gra v ity −1 ∗C sample . 
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Table 3 
Retention time (t R ), calibration range, R ², goodness-of-fit factor (g), bias, repeatability, intermediate precision, matrix effect (ME) ± SD. Concentrations are expressed as 
concentrations of the intact steroid conjugate. 
Compound 
t R 
(min) 
Range 
(ng/ml) 
QC1 
(ng/ml) 
QC2 
(ng/ml) R ² g 
Concentration 
level 
(ng/ml) Bias (%) 
Repeatability 
(%) 
Intermediate 
precision 
(%) IS 
ME 
(%) 
5 ααβdiol3G 17.9 5-800 25 300 
0.9980 
9.5 5 -4.2 4.0 9.7 5 ααβdiol17G-d4 -7.7 
±
2.9 
200 2.5 2.0 2.0 
800 2.5 3.0 4.6 
5 ααβdiol17G 18.9 5-800 25 300 
0.9984 
7.2 5 -6.1 3.7 9.0 5 ααβdiol17G-d4 -7.7 
±
2.9 
200 2.2 2.5 2.5 
800 6.1 3.3 5.4 
5 α-androstane- 
3,17-dione 
28.5 20-400 60 150 
0.9857 
9.1 20 6.6 13.6 16.3 T-d3 -3.3 
±
4.9 
100 -6.4 7.2 7.2 
400 -2.3 9.4 10.0 
5 βαβdiol3G 17.2 5-800 25 300 
0.9992 
4.0 5 1.0 4.6 15.3 5 ααβdiol17G-d4 -7.7 
±
2.9 
200 0.4 1.8 1.8 
800 1.4 2.9 4.6 
5 βαβdiol17G 21.1 5-800 25 300 
0.9982 
8.7 5 -9.8 4.4 7.9 5 ααβdiol17G-d4 -7.7 
±
2.9 
200 1.8 1.7 1.7 
800 1.5 3.4 4.5 
5 β-androstane- 
3,17-dione 
31.7 10-400 35 150 
0.9909 
9.0 50 -0.9 12.7 14.2 T-d3 -3.3 
±
4.9 
200 -0.6 5.1 5.1 
400 1.9 3.5 8.1 
AG 22.1 200- 
12000 1000 4500 0.9995 
3.1 200 -5.7 1.7 9.5 AG-d4 -2.7 
±
2.2 
3000 -5.9 1.7 3.8 
12000 -2.8 3.4 5.0 
AS 18.7 50- 
3000 
250 
1125 0.9970 
5.3 50 5.9 1.4 10.7 AS-d4 
15.6 
±
9.9 
750 10.4 1.2 1.2 
3000 13.9 2.5 5.8 
DHEAS 11.2 20- 
8000 
100 
3000 0.9995 
3.8 20 3.1 1.4 11.3 DHEAS-d5 -2.8 
±
6.6 
2000 3.0 1.3 1.3 
8000 5.8 2.5 5.1 
EpiAS 13.0 15- 
1000 
75 375 
0.9943 
6.4 15 11.5 1.4 12.3 TS-d3 
26.0 
±
10.7 
250 8.6 1.1 1.1 
1000 15.0 2.0 7.7 
EG 16.2 2-120 10 75 
0.9977 
5.3 2 9.1 3.3 14.6 EG-d3 0.9 
±
3.0 
50 5.4 1.8 1.8 
200 11.6 2.8 7.1 
ES 12.5 2-120 10 45 
0.9991 
3.6 2 7.1 2.6 11.0 ES-d3 
40.7 
±
16.6 
30 2.0 0.7 0.7 
120 5.6 2.3 3.6 
EtioG 19.5 200- 
12000 1000 4500 0.9989 
3.5 200 -2.8 1.6 9.6 AG-d4 -2.7 
±
2.2 
( continued on next page ) 
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Table 3 ( continued ) 
Compound t R 
(min) 
Range 
(ng/ml) 
QC1 
(ng/ml) 
QC2 
(ng/ml) 
R ² g 
Concentration 
level 
(ng/ml) 
Bias (%) 
Repeatability 
(%) 
Intermediate 
precision 
(%) 
IS ME 
(%) 
3000 -6.8 1.6 1.6 
12000 3.2 2.9 3.5 
EtioS 17.6 20- 
1000 
100 375 
0.9985 
3.9 20 9.5 1.7 13.5 EtioS-d5 -0.4 
±
7.2 
250 4.1 1.2 1.2 
1000 6.3 2.0 4.2 
T 21.8 0.1-10 0.5 3.75 
0.9909 18.8 
0.1 47.3 17.8 37.0 T-d3 -3.3 
±
4.9 
2.5 10.5 4.7 4.7 
10 2.9 2.8 7.9 
TG 9.0 1-200 5 75 
0.9996 
3.0 1 6.7 2.7 10.3 TG-d3 - 
12.7 
±
13.2 
50 5.3 1.9 1.9 
200 11.7 2.0 7.3 
TS 10.0 1-50 5 
18.75 0.9986 
5.2 1 -4.5 3.3 6.0 TS-d3 
26.0 
±
10.7 
12.5 2.2 0.8 0.8 
50 3.9 2.5 4.8 
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u  3. Results and discussion 
3.1. Method development 
3.1.1. Chromatography 
Separation of isomeric conjugates is a challenging task, espe-
cially when they are present in different concentration ranges. Es-
pecially separation between DHEAS and ES was a challenging task.
Therefore, different analytical columns were tested. Initially, an
OmniSpher C18 column (100 × 2 mm, 3 μm), previously used by
Pozo et al. [12] , was investigated, but the desired separation was
not achieved. An interesting column, the Zorbax Eclipse Plus C18
column (2.1 × 100 mm, 1.8 μm), was used in the work of Esquivel
et al. [6] , allowing the separation of DHEAS and ES. 
As glucuronides and sulfates contain an acidic part, they can be
ionized as [M-H] −. However, some glucuronides and sulfates can
also be ionized in positive mode as [M + H] + or [M + NH 4 ] + . There-
fore the addition of NH 4 OOCH in the mobile phase is suitable for
the detection of these glucuronides and sulfates [ 12 , 23 , 25 , 26 , 34 ]. 
Initially, 1 mM of NH 4 OOCH was added to the mobile phase.
In order to improve peak shape, discussed in the work of Marcos
et al. [34] , the ionic strength of the mobile phase was increased
by adding 20 mM NH 4 OOCH. Because of sensitivity problems, the
concentration of NH 4 OOCH was decreased to 5 mM, which gave a
good compromise between good peak shape and sensitivity and is
in agreement with the findings of Esquivel et al. [6] . 
The gradient described in the work of Pozo et al. [12] was
first investigated, but the separation for the sulfates was not suf-
ficient. The final gradient was based on the one used by Esquivel
et al. [6] but modifications are made since there are glucuronides
included in the method as well. Adjustments were needed for
the separation of AG and EtioG, 5 α-androstane-3,17-dione and
5 β-androstane-3,17-dione and the diol glucuronides. Despite the
fact that it is a long gradient, separation between 5 α- and 5 β-
androstane-3,17-dione and all diol glucuronides was obtained. This
demonstrates another advantage of the developed method, as the
GC-MS screening method is not able to distinguish between the
r  ifferent isomers due to hydrolysis. Fig. 1 illustrates that, even at
he highest calibration level, the diol glucuronides could be sepa-
ated. 
As urine is injected directly onto the column, lifetime of the
olumn was limited. The major issues observed were backpres-
ure increasing quickly, retention time shifts and peak broadening.
ventually separation of the different compounds, especially the
iol glucuronides and EtioS/AS, was determinative. In summary,
uring this study, 5 columns were used (approximating about 3550
njections). 
.2. Sample preparation 
In the first step of the development, turbulent flow online SPE
as investigated as this had already been proven to be an effective
ay of sample clean-up using no sample preparation [41] . 
Previous work showed that phase II metabolites can be detected
ith sufficient sensitivity using a direct injection strategy, without
he need for sample clean-up [ 12 , 35 ]. Therefore, this approach was
pplied. 
The little sample preparation brings a couple of benefits. Next
o the reduced sample volume needed for analysis (300 μl), work-
oad and sample preparation time ( ± 1 day for the routine GC
ethod versus adding internal standard, centrifuging and trans-
erring to a vial for the developed method), there are no param-
ters for hydrolysis and derivatisation that have to be checked as
he intact conjugates can be analysed, avoiding technical errors
escribed by Mareck et al. [21] . By omitting hydrolysis, LLE and
erivatisation, the developed method requires fewer reagents and
s less prone to variation and human errors [17] . 
.3. Validation 
To establish calibration curves and test repeatability and inter-
al bias, steroid stripped urine was used as a surrogate matrix.
his was preferred to other surrogate matrices, including synthetic
rine, as best practice, as in the opinion of the authors it still rep-
esents the best possible resemblance to real urine samples. It Is
L. De Wilde, K. Roels and P. Van Renterghem et al. / Journal of Chromatography A 1624 (2020) 461231 7 
Fig. 1. Separation of the diol glucuronides at the highest calibration level on a new column. 
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1  lear that the stripping process also potentially removes other sub-
tances present in the matrix. Therefore, for selectivity and exter-
al bias, real urine samples were used. The external bias was also
ncluded into the measurement uncertainty calculations. Finally,
he cross validation/comparison of the results of this method with
he routine method, using GC-MS, and analysis of WADA EQAS
amples also shows that the surrogate matrix was adequate. 
.3.1. Linearity 
A linear weighted regression model of 1/X was used for every
ompound except for 5 ααβdiol3G, 5 ααβdiol17G, 5 βαβdiol17G
nd AG where a quadratic weighted regression model was used
ue to the contribution of the natural abundances of the heavier
sotopes in the target analyte [42] . As the g-factor is a more strin-
ent criterion than bias per calibration level, occasionally outliers
ad to be removed from the calibration curves with a maximum of
 per calibration curve. In Table 3 , g-factors are presented for one
f the intermediate precision batches. The g-factor is below 10 for
very compound except for T (18.8). As all calibrators are below
00 ng/ml, a maximum g-factor of 20 is allowed. 
In every batch analysed, all calibration curves were compliant
ith the g-factor, R was higher than 0.98 and bias per calibrator
evel never exceeded 20 %. 
.3.2. Bias and precision 
The results in Table 3 show that bias was the highest for free
 at the lowest level (0.1 ng/ml) which is by far the lowest level
valuated in this work. As free T is a marker of degradation [21] ,
he concentration only becomes important in case it exceeds the
hreshold of 5 % of the total T concentration [38] . Quantification
t such a low level of 0.1 ng/ml is therefore less important. The
ias of all other compounds never exceeded 20 %. Repeatability
nd intermediate precision results have the same trend of being
he highest for testosterone at the lowest level. 
The evaluation of 25 EQAS samples for the determination of
he external bias generated 175 values. Only 6 out of 175 (3.4 %)
-scores were above 2 (questionable z-scores). Z-scores never ex-eeded 3 (unsatisfactory z-scores). The overall bias of these 25
amples was 14.0 %, 16.0 %, 11.8 %, 8.8 %, 5.0 % and 10.2 % for 5 α-
iol, A, 5 β-diol, E, Etio and T respectively. 
.3.3. Matrix effect 
If the matrix effect had been determined in steroid stripped
rine, the contribution of other endogenous steroids would not
ave been taken into account. Therefore, 10 real urine samples
ere spiked with the deuterated internal standards to assess ma-
rix effect [12] . As can be concluded from the results presented in
able 3 , the matrix effect is small despite the fact that it is a di-
ect injection method. It might be that interferences are excluded
ue to the long gradient. The bigger standard deviations can be ex-
lained by the fact that 10 different urine samples were used for
his experiment. 
.3.4. Carry-over 
Only for EtioG (0.01 %) and AG (0.02 %), carry-over could be ob-
erved in the blank matrix sample analysed after the highest cali-
rator. 
.3.5. Measurement uncertainty 
18 intermediate precision measurements and 24 QC measure-
ents (22 for 5 α-diol due to bad peaks) are included in the
alculation of measurement uncertainty. The results, tabulated in
able 4 , meet the criteria described in WADA’s technical document
n EAAS [38] . 
.4. Comparison with routine GC method 
Bland-Altman plots and linear regression plots were chosen to
ompare the developed LC method with the routine GC method
40] for the glucuronidated steroids. The concentrations of these
teroids had to be expressed as the concentrations of the free
teroids. Outliers were not removed. As can be seen from the re-
ults shown in Fig. 2 , the mean differences approximate 0 (T: -
.6; E: -0.4; Etio: 43.3; 5 α-diol: -6.2; 5 β-diol: -19.5), except for
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Fig. 2. Left side: Comparison between the developed LC method and the routine GC method represented by Bland-Altman plots. The yellow line represents the mean 
difference; the range in the orange lines contains 95 % of all values. Right side: Correlation between the routine GC method and the developed LC method. 
Fig. 3. Steroid profile for one volunteer during an excretion study of oral testosterone undecanoate. The LC results are expressed as concentrations of the free steroids and 
are presented by dots, the GC results are presented by triangles. For the LC results, 5 αdiol = 5 ααβdiol3G + 5 ααβdiol17G; 5 βdiol = 5 βαβdiol3G + 5 βαβdiol17G. 
 
 
 
 
 
 
 
 
 
[
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8  
b  
c  A (-426.7). A Bland-Altman plot only gives information about the
absolute difference between two measurements. When looking at
the higher concentrations of A, a bigger absolute difference can be
seen while the relative difference is in line with the lower concen-
trations. The linear regression plots show the correlation between
the two methods. The slope of each regression curve approximates
1 (5 α-diol: 0.97; 5 β-diol: 1.11; A: 1.09; E: 0.97; Etio: 0.89 and T:
1.03), meaning that there is a good correlation between both meth-
ods. 
5  The results of the comparison with the routine GC method
40] demonstrate that the developed LC method is fit for purpose. 
.4.1. Measuring diol glucuronides separately 
The concentrations of the diol glucuronides were compared in
1 samples. After performing a Wilcoxon Signed Rank Test, it can
e concluded that the concentration of 17-glucuronide is signifi-
antly higher than the concentration of the 3-glucuronide for both
 α-diol glucuronide (58 out of 81, Z = -4.9; p = 7.6 E-7) and 5 β-
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Table 4 
Measurement uncertainty for 5 α-diolG, AG, 5 β-diolG, EG, EtioG 
and TG at levels LOQ, QC1 and QC2. 
U c LOQ (%) U c QC1 (5LOQ) (%) U c QC2 (%) 
5 α-diolG 17.3 18.8 17.2 
AG 19.0 16.8 17.9 
5 β-diolG 17.2 14.8 14.8 
EG 17.8 13.3 12.5 
EtioG 10.8 6.8 9.1 
TG 18.2 12.9 11.8 
Fig. 4. 5 βαβdiol17G/5 βαβdiol3G after the oral administration of testosterone un- 
decanoate. The orange line represents the 99 % reference limit (mean + 3x SD). 
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aiol glucuronide (72 out of 81, Z = -7.3; p = 2.6 E-13) in the ma-
ority of the samples. 
.5. Excretion study 
In Fig. 3 , the steroid profile for one volunteer analysed with the
eveloped method is presented together with his steroid profile
nalysed by the routine GC method [40] . In order to make a com-
arison, concentrations of glucuronidated steroids were expressed
s concentrations of the free steroids. As expected, the T/E ratio
eaches a maximum (T/E = 40) after 2 hours post-administration
8] . The concentrations of the metabolites also increase soon after
he administration. The same trend can be seen for both methods
nd shows the similarity between the two methods. 
Fig. 4 shows the 5 βαβdiol17G/5 βαβdiol3G ratio after the
ral administration of testosterone undecanoate for the same vol-Fig. 5. TG/EG and EpiAS/ES after the oral administration of TU for volunteer 6. nteer. The pre-administration samples were used to calculate
he 99 % reference limit (mean + 3x standard deviation (SD)).
 βαβdiol17G/5 βαβdiol3G exceeded the individual threshold for 5
olunteers. 
In the research of Esquivel et al. [19] , a single dose of 120 mg
U was administered. AS/ES and EpiAS/ES were found to be the
est candidates for the detection of oral T misuse and resulted
n longer detection times compared to the T/E ratio. In our study,
ainly the results for volunteer 6 were similar to the ones of Es-
uivel et al. [19] ( Fig. 5 ). This was less pronounced for the other
olunteers. 
. Conclusion 
An LC-method for the simultaneous detection of intact steroid
lucuronides and sulfates was developed and validated, which is
ompliant with the quality criteria established by WADA for the
eporting of analytical results of steroid profiling data. As all pa-
ameters of the current steroid profile are included, the developed
teroid profile screening method, in only 300 μl of urine, could be
sed as an alternative for the GC-MS based methods. The work-
oad is greatly reduced compared to the routine GC method as
here is no sample preparation, no hydrolysis and no derivatisa-
ion because of the dilute-and-shoot protocol. By analysing routine
nd EQAS samples, the method was found to be fit for purpose. A
estosterone undecanoate administration study confirmed the im-
ortance of expanding the current steroid profile with steroid sul-
ates. 
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